Wednesday, September 16, 2026
ExploreSearch
Finance Via News
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
News articleYahoo Finance· April 9, 2026

ImmunityBio Reports Net Product Revenue Increased Nearly 2.7 Times Year-Over-Year to Record $44 Million in Q1 2026 and $381 Million in Cash and Marketable Securities

View original at finance.yahoo.com
“The Company ended the quarter with an estimated $380.9 million in cash, cash equivalents and marketable securities as of March 31, 2026.”
Verbatim excerpt from the source · Yahoo Finance · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • Following strong growth in 2025, ImmunityBio is focused on scaling in the U.S. and expanding across an increasing number of global markets

    60% confidence

  • ANKTIVA's continued momentum reflects growing physician adoption and disciplined commercial execution

    60% confidence

  • Full enrollment of the pivotal BCG-naïve CIS trial with IDMC confirmation of adequate statistical power further strengthen the expanding body of clinical evidence supporting ANKTIVA in the NMIBC bladder cancer setting

    60% confidence

  • Supplemental BLA submission for BCG-naïve indication is on track for 2026

    60% confidence

  • The sustained momentum of ANKTIVA reflects its growing commercial adoption in the BCG-unresponsive NMIBC CIS setting and feedback from treating urologists has been consistently positive

    60% confidence

Cited in these Via News reports

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
AI's 'Show-Me' Reckoning: Earnings Divergence, Executive Exodus, and Regulatory Tightening
Investors are shifting from rewarding AI narratives to demanding tangible results, evidenced by Adobe's weak guidance despite user-growth emphasis, Palantir's stock decline even after winning the Army's TITAN contract, and UiPath's contrasting guidance raise. Simultaneously, high-profile safety-driven departures from Anthropic and Google, plus new regulatory actions (California's under-16 social media ban, Anthropic's misuse-blocking disclosures), signal mounting scrutiny of AI's societal and financial risk profile even as fintech-adjacent funding (Socure) continues.
Our read on the data ›
Signals we're tracking
Satellite-Terrestrial Network Integration Acceleration
Increased investment and launches in hybrid satellite-cellular networks across telecom industry; competitive responses from other carriers; regulatory activity around satellite spectrum; expansion of emergency/rural connectivity use cases
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,981
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,981 facts checked against source5,288 source documents archived
Query this data → isubstrate.com
ImmunityBio Reports Net Product Revenue Increased Nearly 2.7 Times Year-Over-Year to Record $44 Million in Q1 2026 and $381 Million in Cash and Marketable Securities — Source | Via News | Finance Via News